Doxorubicin Market By Application (Ovarian, Multiple Myeloma, Kaposi Sarcoma, Leukemia, Bone Sarcoma, Breast, Endometrial, Gastric, Liver, Kidney, Other Cancers) And Segment Forecasts, 2013 - 2024

  • ID: 3989903
  • Report
  • 84 pages
  • Grand View Research
1 of 3
The global doxorubicin market was valued at USD 0.81 billion in 2015 and is expected to reach a value of USD 1.38 billion by 2024. The growing number of players in the market to control the shortage of the drug is one of the crucial factors that is expected to drive the market in the coming few years. Some of the doxorubicin manufacturers are Ortho Biotech Products, LP, Ben Venue Laboratories, Inc., and Bristol-Myers Squibb Company. The increasing indication of doxorubicin drug in various applications such as AIDS related Kaposi Sarcoma, multiple myeloma, neuroblastoma, osteosarcoma, and ovarian cancer signifies the growth in demand for the drug. The technological advancement in the drug formulations to overcome the adverse effects on health and also introduces various types of drug delivery systems such as nanoparticles or liposomal coated are some of the pivotal factors that are impelling the industry growth.

The U.S. government had issued an executive order to overcome the shortage of life saving drugs, chemotherapy agents, and critically needed drugs in the U.S. region, is one of the indicators accounted for the increasing number of players in this sector. Based on the estimates of Surveillance, Epidemiology, and End Results (SEER), the anticipated number of malignancy cases in 2016 are listed below: -

Leukemia 60,140

Breast cancer 2,46,660

Endometrial cancer 60,050

Gastric cancer 26,370

Liver cancer 39,230

Kidney Cancer 62,700

According to the estimates of the Leukemia & Lymphoma Society in 2016, about 60,140 people are anticipated to be diagnosed with leukemia. The growing prevalence and subsequently increasing survival is one of the factors that indicates the technological advancement and growing adoption of new treatment procedures.

Further Key Findings from the Study Suggest:

In 2015, breast cancer is the largest application of doxorubicin market, having a share of around 21.1%. The growing demand for the drug in combination therapy with cisplatin is one of the pivotal factors that are expected to impel the doxorubicin market.

Liver cancer segment is the fastest growing application in this sector. The growing demand for the drug in combination and mono chemotherapies to treat liver cancer over other anticancer drugs is one of the crucial factors that is expected to boost the industry growth.

In 2015, North America held majority of market share of over 48.8% in the global doxorubicin market. The presence of dominating market players such as Johnson & Johnson and Sun Pharmaceuticals Industries Ltd. and rising awareness regarding efficacious drug alternatives are few of the key factors attributed to the regions high market share.

Asia Pacific is the fastest growing region in this market. The presence of unmet demand for anti-cancer treatment and rapidly growing pharmaceutical industries in countries such as China, Japan, and India are among some factors that are expected to drive the market in the coming few years.

Some of the key market players are Sun Pharmaceutical Industries Ltd., Pfizer, Inc., Cipla, Inc., Cadila Pharmaceuticals, and SRS Pharmaceuticals Pvt. Ltd.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1 Executive Summary
2 Market Snapshot
3 Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Increasing number of market players
3.1.1.2 Increasing application of doxorubicin
3.1.1.3 Growing number of cancer cases
3.1.2 Market restraint analysis
3.1.2.1 Supply demand gap
3.2 Penetration & Growth Prospect Mapping
3.3 Doxorubicin Market- SWOT Analysis, by Factor (Political &Legal, Economic, and Technological)
3.4 Industry Analysis - Porter’s
4 Market Categorization 1: Application Estimates & Trend Analysis
4.1 Doxorubicin Market: ApplicationMovement Analysis
4.2 Ovarian Cancer
4.2.1 Ovarian cancer market estimates and forecasts, 2013 - 2024 (USD Million)
4.3 Multiple Myeloma
4.3.1 Multiple myeloma market estimates and forecasts, 2013 - 2024 (USD Million)
4.4 Kaposi Sarcoma
4.4.1 Kaposi Sarcoma market estimates and forecasts, 2013 - 2024 (USD Million)
4.5 Leukemia
4.5.1 Leukemia market estimates and forecasts, 2013 - 2024 (USD Million)
4.6 Bone sarcoma
4.6.1 Bone sarcoma market estimates and forecasts, 2013 - 2024 (USD Million)
4.7 Breast cancer
4.7.1 Breast cancer market estimates and forecasts, 2013 - 2024 (USD Million)
4.8 Endometrial cancer
4.8.1 Endometrial cancer market estimates and forecasts, 2013 - 2024 (USD Million)
4.9 Gastric cancer
4.9.1 Gastric cancer market estimates and forecasts, 2013 - 2024 (USD Million)
4.10 Liver cancer
4.10.1 Liver cancer market estimates and forecasts, 2013 - 2024 (USD Million)
4.11 Kidney cancer
4.11.1 Kidney cancer market estimates and forecasts, 2013 - 2024 (USD Million)
4.12 Other cancer
4.12.1 Other cancer market estimates and forecasts, 2013 - 2024 (USD Million)
5 Market Categorization 4: Regional Estimates & Trend Analysis
5.1 Doxorubicin Market Share by Region, 2013 & 2024
5.2 North America
5.2.1 North America doxorubicin market estimates and forecasts, by application 2013 - 2024(USD Million)
5.2.2 U.S.
5.2.2.1 U.S. doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
5.2.3 Canada
5.2.3.1 Canada doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
5.3 Europe
5.3.1 Europe doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
5.3.2 Germany
5.3.2.1 Germany doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
5.3.3 UK
5.3.3.1 UK doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
5.4 Asia Pacific
5.4.1 Asia Pacific doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
5.4.2 Japan
5.4.2.1 Japan doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
5.4.3 China
5.4.3.1 China doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
5.5 Latin America
5.5.1 Latin America doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
5.5.2 Brazil
5.5.2.1 Brazil doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
5.5.3 Mexico
5.5.3.1 Mexico doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
5.6 MEA
5.6.1 MEA doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
5.6.2 South Africa
5.6.2.1 South Africa doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
6 Competitive Landscape
6.1 Strategy Framework
6.2 Market Participation Categorization
6.3 Company Profiles
6.3.1 Pfizer, Inc.
6.3.1.1 Company overview
6.3.1.2 Financial performance
6.3.1.3 Product benchmarking
6.3.1.4 Strategic initiatives
6.3.2 Sun Pharmaceutical Industries Ltd.
6.3.2.1 Company overview
6.3.2.2 Financial performance
6.3.2.3 Product benchmarking
6.3.2.4 Strategic initiatives
6.3.3 Cipla, Inc.
6.3.3.1 Company overview
6.3.3.2 Financial performance
6.3.3.3 Product benchmarking
6.3.3.4 Strategic initiatives
6.3.4 Cadila Pharmaceuticals
6.3.4.1 Company overview
6.3.4.2 Financial performance
6.3.4.3 Product benchmarking
6.3.4.4 Strategic initiatives
6.3.5 SRS PHARMACEUTICALS PVT. LTD.
6.3.5.1 Company overview
6.3.5.2 Financial performance
6.3.5.3 Product benchmarking
6.3.5.4 Strategic initiatives
6.3.6 Janssen Products, LP
6.3.6.1 Company overview
6.3.6.2 Financial performance
6.3.6.3 Product benchmarking
6.3.6.4 Strategic initiatives

List of Tables

Table 1 Approved doxorubicin products, by approval date and company name
Table 2 Estimated number of cancer cases and deaths, by type in 2016
Table 3 Cancer Prevalence, by type and region in 2012
Table 4 Number of patients treated using doxorubicin, 2012
Table 5 North America doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 6 Estimated new cases of cancer, by type and age, 2015
Table 7 U.S. doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 8 Canada doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 9 Europe doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 10 UK doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 11 Germany doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 12 Asia Pacific doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 13 Number of cancer cases by site in 2015
Table 14 Japan doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 15 China doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 16 Latin America doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 17 Brazil doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 18 Mexico doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 19 MEA doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 20 South Africa doxorubicin market, by application, 2013 - 2024 (USD Million)

List of Figures

Figure 1 Market summary
Figure 2 Market trends & outlook
Figure 3 Market segmentation & scope
Figure 4 Market driver relevance analysis (Current & future impact)
Figure 5 Market restraint relevance analysis (Current & future impact)
Figure 6 Penetration & growth prospect mapping
Figure 7 SWOT analysis, by factor (Political & legal, economic and technological)
Figure 8 Porter’s Five Forces Analysis
Figure 9 Doxorubicin Market: Application outlook key takeaways
Figure 10 Doxorubicin Market: Application movement analysis
Figure 11 Ovarian market estimates and forecasts, 2013 - 2024 (USD Million)
Figure 12 Multiple myeloma market estimates and forecasts, 2013 - 2024 (USD Million)
Figure 13 Kaposi sarcoma market estimates and forecasts, 2013 - 2024 (USD Million)
Figure 14 Leukemia market estimates and forecasts, 2013 - 2024 (USD Million)
Figure 15 Bone sarcoma market estimates and forecasts, 2013 - 2024 (USD Million)
Figure 16 Breast cancer market estimates and forecasts, 2013 - 2024 (USD Million)
Figure 17 Endometrial cancer market estimates and forecasts, 2013 - 2024 (USD Million)
Figure 18 Gastric cancer market estimates and forecasts, 2013 - 2024 (USD Million)
Figure 19 Liver cancer market estimates and forecasts, 2013 - 2024 (USD Million)
Figure 20 Kidney cancer market estimates and forecasts, 2013 - 2024 (USD Million)
Figure 21 Other cancer application market estimates and forecasts, 2013 - 2024 (USD Million)
Figure 22 Regional market place: Key takeaways
Figure 23 Regional outlook, 2015 & 2024
Figure 24 North America doxorubicin market estimates and forecasts,by application, 2013-2024(USD Million)
Figure 25 U.S. doxorubicin market estimates and forecasts, by application, 2013-2024(USD Million)
Figure 26 Canada doxorubicin market estimates and forecasts, by application, 2013-2024(USD Million)
Figure 27 Europe doxorubicin market estimates and forecasts, by application, 2013-2024(USD Million)
Figure 28 Germany doxorubicin market estimates and forecasts, by application, 2013-2024(USD Million)
Figure 29 UK doxorubicin market estimates and forecasts, by application, 2013-2024(USD Million)
Figure 30 Asia Pacific doxorubicin market estimates and forecasts, by application, 2013 - 2024 (USD Million)
Figure 31 Japan doxorubicin market estimates and forecasts, by application, 2013- 2024(USD Million)
Figure 32 Chinadoxorubicin market estimates and forecasts, by application, 2013 - 2024(USD Million)
Figure 33 Latin America doxorubicin market estimates and forecasts, by application, 2013-2024 (USD Million)
Figure 34 Brazildoxorubicin market estimates and forecasts, by application, 2013 - 2024 (USD Million)
Figure 35 Mexico doxorubicin market estimates and forecasts,by application, 2013 - 2024(USD Million)
Figure 36 MEA doxorubicin market estimates and forecasts,by application 2013-2024(USD Million)
Figure 37 South Africa doxorubicin market estimates and forecasts,by application, 2013 - 2024(USD Million)
Figure 38 Strategy framework
Figure 39 Participant categorization
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll